$RLMD News

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock Today

Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed

Relmada Therapeutics, Inc. Q1 2026 Earnings Call Summary

Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...

Relmada Therapeutics Q1 Earnings Call Highlights